Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
NEWARK, Calif., March 07, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the 28th Annual ROTH Conference in Dana Point, California. The presentation is scheduled for Monday, March 14, 2016 at 10:30 a.m. PDT (1:30 p.m. EDT).
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payers we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000
